...Momenta Pharmaceuticals Inc. an option to license a preclinical mAb program against cancer-specific glycans containing Neu5Gc...
...Jolla, Calif. Targets MUC1 (CD227) - Mucin 1 MUC16 (CA125) - Mucin 16 Neu5Gc - N-glycolylneuraminic acid...
...of Cancer National Cancer Institute Siamab Therapeutics Inc. University of California San Diego CD44 Mucin 1 (MUC1) (CD227) Mucin 16 (MUC16) (CA125) N-glycolylneuraminic acid (Neu5GC) Sialosyl-Tn...

...an option to license a preclinical mAb program against cancer-specific glycans containing non-human sialic acid N-glycolylneuraminic acid (Neu5Gc)...
...products to treat and prevent cancer and chronic inflammatory diseases associated with the ingestion of Neu5Gc...

...Pharmaceuticals Inc. (NASDAQ:MNTA) an option to license a preclinical mAb program against cancer-specific glycans containing N-glycolylneuraminic acid (Neu5Gc)...
...products to treat and prevent cancer and chronic inflammatory diseases associated with the ingestion of Neu5Gc...

...with 5 mM Neu5Ac, secreted and membrane proteins had lower levels of immunogenic sialic acid N-glycolylneuraminic acid (Neu5Gc)...
...doi:10.1038/scibx.2010.934 Published online Aug. 5, 2010 Patent application filed for use of Neu5Ac to eliminate Neu5Gc...

...by a non-human, cell-surface sialic acid called N-glycolylneuraminic acid (Neu5Gc). Human cells are genetically unable to make Neu5Gc...
...the stem cells renders them useless as therapeutics as human antibodies attacks cells contaminated with Neu5Gc...

...funding in the U.S., have been contaminated by a non-human, cell-surface sialic acid called N-glycolylneuraminic acid (Neu5Gc). Neu5Gc...
...Neu5Gc was incorporated into the stem cells from laboratory cultures that contained animal sources of Neu5Gc...